Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label attachment file name title
tabling member	label

Search

1061227

	registered interest
	date	14/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	General Practitioners: Oxford
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of trends in the level of GP appointment waiting times in Oxford.
	tabling member constituency	Oxford East
	tabling member printed	Anneliese Dodds
	uin	221835
	answer	answer is ministerial correction date of answer 19/02/2019 answer text <p>The proportion of general practitioner (GP) appointments by date and time between booking date and appointment date in Oxford Clinical Commissioning Group for the months November 2017 to December 2018 is presented in the attached table. The data on GP appointments are from a new data collection and are still experimental i.e. the data and collection method are still being refined and improved. NHS Digital’s data on ‘time from booking to appointment’ does not take into consideration that many patients will be appropriately booking ahead as part of the continuity of care they receive for long-term conditions. Other factors that drive the time from a booking to an appointment include appointment availability at the practice, patient availability, the urgency of the appointment and GP advice.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/02/2019 17:24:06 question first ministerially corrected 21/02/2019 10:24:53 answering member 4067 label Biography information for Steve Brine attachment 1 file name 221835 formatted table.docx title GP appointments Oxford CCG previous answer version 103151 answering member constituency Winchester answering member printed Steve Brine answering member 4067 label Biography information for Steve Brine attachment 1 file name PQ221587 attached tables.docx title PQ221835 attached table
	tabling member	4657 label Biography information for Anneliese Dodds

1038941

	registered interest
	date	10/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Hormone Replacement Therapy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with Cabinet colleagues on reducing the cost of hormone replacement therapy for patients who pay multiple prescription charges for medication with more than one ingredient.
	tabling member constituency	Oxford East
	tabling member printed	Anneliese Dodds
	uin	207273
	answer	answer is ministerial correction date of answer 15/01/2019 answer text <p>Unless a valid exemption has been declared the statutory applicable charge of £8.80 is payable for each prescription item, such as a quantity of a drug, dispensed in the community in England. The Government has no plans to change this position in respect of combination packs of hormone replacement therapy medication comprised of multiple drugs. Accordingly, no recent discussions about this matter have taken place at Cabinet level.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/01/2019 16:04:06 answering member 4067 label Biography information for Steve Brine
	tabling member	4657 label Biography information for Anneliese Dodds

1087225

	registered interest
	date	12/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Tomography: Procurement
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what engagement with (a) patients, (b) the public and (c) other stakeholders NHS England undertook for the second phase of tendering PET-CT services across England.
	tabling member constituency	Oxford East
	tabling member printed	Anneliese Dodds
	uin	231557
	answer	answer is ministerial correction date of answer 15/03/2019 answer text <p>NHS England completed a 30-day public engagement about the Phase II procurement proposals between January – February 2016. This was publicised on both NHS England’s website and its Engage portal. Further details of public engagement can be found at the following link:</p><p> </p><p><a href="https://www.engage.england.nhs.uk/survey/pet-ct-services/" target="_blank">https://www.engage.england.nhs.uk/survey/pet-ct-services/</a></p><p> </p><p>As this was a public engagement exercise it was open to all stakeholders, including patients and members of the public. NHS England is committed to ensuring that the public are involved in decision making. Where new service proposals would result in substantial development or variation, such as location change, further public involvement activities will be undertaken.</p><p> </p><p>In accordance with established procurement practices, which ensure impartial decision making, NHS England has not consulted with any stakeholder groups or hon. Members during the procurement process.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 231558 question first answered 15/03/2019 13:39:23 answering member 4067 label Biography information for Steve Brine
	tabling member	4657 label Biography information for Anneliese Dodds

1087229

	registered interest
	date	12/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Tomography: Procurement
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether NHS England consulted (a) MPs, (b) cancer charities (c) doctors' groups and (d) cancer specialists during the second phase of the PET-CT services tendering process throughout England; and how many people were consulted during that process.
	tabling member constituency	Oxford East
	tabling member printed	Anneliese Dodds
	uin	231558
	answer	answer is ministerial correction date of answer 15/03/2019 answer text <p>NHS England completed a 30-day public engagement about the Phase II procurement proposals between January – February 2016. This was publicised on both NHS England’s website and its Engage portal. Further details of public engagement can be found at the following link:</p><p> </p><p><a href="https://www.engage.england.nhs.uk/survey/pet-ct-services/" target="_blank">https://www.engage.england.nhs.uk/survey/pet-ct-services/</a></p><p> </p><p>As this was a public engagement exercise it was open to all stakeholders, including patients and members of the public. NHS England is committed to ensuring that the public are involved in decision making. Where new service proposals would result in substantial development or variation, such as location change, further public involvement activities will be undertaken.</p><p> </p><p>In accordance with established procurement practices, which ensure impartial decision making, NHS England has not consulted with any stakeholder groups or hon. Members during the procurement process.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 231557 question first answered 15/03/2019 13:39:23 answering member 4067 label Biography information for Steve Brine
	tabling member	4657 label Biography information for Anneliese Dodds

1091298

	registered interest
	date	19/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Tomography: Oxfordshire
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 15 March 2019 to Question 231557 on Tomography: Procurement, what additional engagement was undertaken by the NHS on the effect of the proposed privatisation of the PET-CT scan service in Oxford on the location of those services outside Oxford.
	tabling member constituency	Oxford East
	tabling member printed	Anneliese Dodds
	uin	234237
	answer	answer is ministerial correction date of answer 22/03/2019 answer text <p>No additional engagement has been undertaken by NHS England to that outlined in the previous response.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/03/2019 14:15:14 answering member 4067 label Biography information for Steve Brine
	tabling member	4657 label Biography information for Anneliese Dodds

758714

	registered interest
	date	07/09/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will provide an update on negotiations between NICE and the drug manufacturer Vertex on the potential use of the drug Orkambi.
	tabling member constituency	Oxford East
	tabling member printed	Anneliese Dodds
	uin	9489
	answer	answer is ministerial correction date of answer 14/09/2017 answer text <p>The National Institute for Health and Care Excellence (NICE) published technology appraisal guidance on the use of lumacaftor-ivacaftor (Orkambi) for the treatment of cystic fibrosis in July 2016. NICE plans to review its guidance to determine whether it should be updated in the light of any new evidence in 2019.</p><p> </p><p>If significant new evidence comes to light before the scheduled review date, NICE has processes in place to bring forward a review. NICE remains open to a further approach from the company, with new evidence or a revised price. Although there has been recent correspondence between NHS England and the company, NICE has not yet received any fresh proposals from the company.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/09/2017 13:54:44 answering member 4067 label Biography information for Steve Brine
	tabling member	4657 label Biography information for Anneliese Dodds

788522

	registered interest
	date	13/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neuromuscular Disorders: Physiotherapy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to increase the provision of specialist physiotherapy for children and adults with muscle-wasting conditions.
	tabling member constituency	Oxford East
	tabling member printed	Anneliese Dodds
	uin	112488
	answer	answer is ministerial correction date of answer 16/11/2017 answer text <p>The provision of specialist physiotherapy for muscle-wasting conditions, or neuromuscular disorders, is a local matter. NHS England has published service specifications for neurological care for both children and adults. These include exemplar service specifications for neuromuscular conditions, inclusive of muscle-wasting conditions, and set out what providers must have in place to offer evidence-based, safe and effective services. This includes access to physiotherapy. This guidance can be found by following the links below:</p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/e09-paedi-neurology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/e09-paedi-neurology.pdf</a></p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/d04-neurosci-spec-neuro.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/d04-neurosci-spec-neuro.pdf</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/11/2017 12:22:03 answering member 4067 label Biography information for Steve Brine
	tabling member	4657 label Biography information for Anneliese Dodds

789075

	registered interest
	date	14/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	General Practitioners: Fees and Charges
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when the fee chargeable by NHS general practices for providing medical information to patients for the purposes of other public authorities was last reviewed by his Department; and if he will make a statement.
	tabling member constituency	Oxford East
	tabling member printed	Anneliese Dodds
	uin	113026
	answer	answer is ministerial correction date of answer 22/11/2017 answer text <p>NHS England contracts with general practitioners (GPs) as independent providers of medical services for the National Health Service. Under the terms of their contract, GPs are required to provide certain medical reports or complete certain forms for which a medical report is required by other legislation, for example, the Social Security Administration Act, free of charge to their registered patients.</p><p> </p><p>Outside their contractual requirements, GPs also offer a variety of other services which successive governments have regarded as private matters between the patient and the GP. In such cases, decisions on whether to charge a fee and the level of the fee charged are at the GP’s discretion.</p><p> </p><p>Where legislation requires a medical certificate, or report, the relevant Government Department enters into arrangements with the British Medical Association on the level of fees which will be paid to GPs for providing the required information. Such arrangements are formalised through the provisions of the GP contract.</p><p> </p><p>As these are private arrangements between GP practices and other organisations, the Department does not review the level of fees.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/11/2017 14:50:32 answering member 4067 label Biography information for Steve Brine
	tabling member	4657 label Biography information for Anneliese Dodds

790987

	registered interest
	date	16/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	General Practitioners: Pay
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment has been made of the potential effect of the differential pay for GPs working in standard general practices, out-of-hours services, or seven-day-access services on recruitment and staffing levels; and if he will make a statement.
	tabling member constituency	Oxford East
	tabling member printed	Anneliese Dodds
	uin	113506
	answer	answer is ministerial correction date of answer 23/11/2017 answer text <p>Doctors employed by general practitioner (GP) practices will carry out a variety of different duties depending on the needs of the service locally. We know practices will want to develop a local employment offer which best attracts and retains the staff they need to deliver care and advice to patients. GPs also need to recruit, retain and motivate staff in an affordable way.</p><p>However, GP practices are required to employ doctors on terms no less favourable than those agreed with the General Practitioners’ Committee of the British Medical Association and contained in the document entitled “Model terms and conditions of service for a salaried practitioner employed by a GMS practice”.</p><p>We continue to explore workforce issues in general practice with relevant stakeholders.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/11/2017 12:28:14 answering member 4067 label Biography information for Steve Brine
	tabling member	4657 label Biography information for Anneliese Dodds

928742

	registered interest
	date	21/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rare Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to revise the rare disease strategy ahead of the UK leaving the EU.
	tabling member constituency	Oxford East
	tabling member printed	Anneliese Dodds
	uin	156485
	answer	answer is ministerial correction date of answer 28/06/2018 answer text <p>With the aim of improving the lives of all those affected by a rare disease, the United Kingdom Government published the UK Strategy for Rare Diseases in 2013, a high-level framework containing 51 commitments which sets out a 7-year strategic vision (2013-2020).</p><p> </p><p>The Government is committed to implementing the Strategy’s commitments and has, in January 2018, published Implementation Plans setting out its actions for England.</p><p> </p><p>The UK Rare Disease Policy Board is the UK-wide body responsible for facilitating the co-ordination of policy development and meeting the commitments set out in the UK Strategy for Rare Diseases. The Strategy is kept under review to take account of new developments including the outcome of negotiations with the European Union.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 28/06/2018 11:20:40 answering member 4067 label Biography information for Steve Brine
	tabling member	4657 label Biography information for Anneliese Dodds